AHFS February 2024 Update

This update contains 11 new monographs, 24 revised monographs, and 9 new MedWatch alerts.

New monographs: ADAMTS13, Recombinant-krhn; Capivasertib; Efbemalenograstim Alfa-vuxw; Fruquintinib; Ipratropium Bromide (EENT); Iptacopan Hydrochloride; levOCARNitine; Meningococcal Groups A, B, C, W, and Y Vaccine; Nirogacestat Hydrobromide; Repotrectinib; Zilucoplan Sodium.

Revised monographs: Alpelisib; Amifampridine Phosphate; Ansuvimab-zykl; Atazanavir Sulfate; Atoltivimab, Maftivimab, and Odesivimab-ebgn; Avalglucosidase Alfa-ngpt; Axitinib; Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate; Cladribine (Immunomodulatory Agent); Denosumab; Doravirine; Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate; Entecavir; Fosdenopterin Hydrobromide; Futibatinib; Lenalidomide; Lumasiran Sodium; Ocrelizumab; Pasireotide; Pegcetacoplan; Siponimod Fumarate; Teprotumumab-trbw; Tezepelumab-ekko; Vibegron.

New MedWatch alerts on the following monographs: Axicabtagene Ciloleucel; Brexucabtagene Autoleucel; Ciltacabtagene Autoleucel; cloBAZam; Eflornithine; Idecabtagene Vicleucel; LevETIRAcetam; Lisocabtagene Maraleucel; Tisagenlecleucel.